Stock News

Sound Finl Bancorp (SFBC) Valuation Rose While Fj Capital Management Has Lifted Its Position; As Alexion Pharmaceuticals (ALXN) Stock Value Declined, Holder Kazazian Asset Management Boosted Position

Sound Financial Bancorp, Inc. (NASDAQ:SFBC) Logo

Fj Capital Management Llc increased its stake in Sound Finl Bancorp Inc (SFBC) by 22.03% based on its latest 2017Q4 regulatory filing with the SEC. Fj Capital Management Llc bought 16,300 shares as the company’s stock rose 10.41% while stock markets declined. The hedge fund held 90,300 shares of the finance company at the end of 2017Q4, valued at $3.07 million, up from 74,000 at the end of the previous reported quarter. Fj Capital Management Llc who had been investing in Sound Finl Bancorp Inc for a number of months, seems to be bullish on the $93.75 million market cap company. The stock decreased 1.94% or $0.75 during the last trading session, reaching $38. About 78 shares traded. Sound Financial Bancorp, Inc. (NASDAQ:SFBC) has risen 27.56% since May 17, 2017 and is uptrending. It has outperformed by 16.01% the S&P500.

Kazazian Asset Management Llc increased its stake in Alexion Pharmaceuticals Inc (ALXN) by 62.83% based on its latest 2017Q4 regulatory filing with the SEC. Kazazian Asset Management Llc bought 6,669 shares as the company’s stock declined 8.80% with the market. The institutional investor held 17,283 shares of the health care company at the end of 2017Q4, valued at $2.07M, up from 10,614 at the end of the previous reported quarter. Kazazian Asset Management Llc who had been investing in Alexion Pharmaceuticals Inc for a number of months, seems to be bullish on the $26.93 billion market cap company. The stock increased 0.02% or $0.03 during the last trading session, reaching $121.03. About 123,500 shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 8.84% since May 17, 2017 and is downtrending. It has underperformed by 20.39% the S&P500.

Investors sentiment decreased to 1.03 in Q4 2017. Its down 0.14, from 1.17 in 2017Q3. It is negative, as 65 investors sold ALXN shares while 171 reduced holdings. 64 funds opened positions while 178 raised stakes. 204.38 million shares or 1.21% less from 206.89 million shares in 2017Q3 were reported. Alliancebernstein Ltd Partnership invested in 0.05% or 605,467 shares. Fort Washington Inv Advsr Oh invested in 0% or 3,749 shares. Point72 Asset Mgmt Ltd Partnership invested 0.11% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). California State Teachers Retirement Sys stated it has 0.09% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Bank Of New York Mellon has 3.11M shares. Seatown Pte Limited accumulated 111,000 shares or 1.26% of the stock. Bartlett & Llc invested 0% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Caisse De Depot Et Placement Du Quebec invested 0.01% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). 4,586 are held by Cim Inv Mangement. Neuberger Berman Group Incorporated Ltd Liability Corp has 321,588 shares for 0.04% of their portfolio. Vanguard Group Inc reported 15.20M shares. Green Square Cap Limited Liability reported 0.06% stake. 4,833 were reported by Brown Advisory. 1.23M were accumulated by Balyasny Asset Mngmt Limited Liability. Meag Munich Ergo Kapitalanlagegesellschaft Mbh reported 21,713 shares.

Kazazian Asset Management Llc, which manages about $97.87M US Long portfolio, decreased its stake in Biogen Inc (NASDAQ:BIIB) by 1,272 shares to 9,229 shares, valued at $2.94 million in 2017Q4, according to the filing.

Since January 2, 2018, it had 1 insider buy, and 12 sales for $3.41 million activity. O’Neill Julie sold $556,776 worth of stock. HANTSON LUDWIG had sold 13,245 shares worth $1.54 million. COUGHLIN CHRISTOPHER J bought $1.21 million worth of stock. 6,079 shares were sold by Clancy Paul J, worth $707,048 on Tuesday, February 6. The insider Moriarty John B sold 1,261 shares worth $147,865. Another trade for 1,459 shares valued at $169,696 was made by Franchini Indrani Lall on Tuesday, February 6.

More notable recent Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) news were published by: 247Wallst.com which released: “4 Red-Hot Biotech Stocks to Buy Before Earnings” on April 18, 2018, also Streetinsider.com with their article: “Alexion Pharma (ALXN) Patent on Soliris Revoked in Brazil” published on April 20, 2018, Streetinsider.com published: “Vertex Pharma (VRTX), Alexion Pharma (ALXN) Least Impacted from Trump Drug Policies – RBC” on May 15, 2018. More interesting news about Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) were released by: Benzinga.com and their article: “Benzinga’s Insider Buys Of The Week: Alexion Pharmaceuticals, Sohu.com And More” published on May 06, 2018 as well as Nasdaq.com‘s news article titled: “3 Top Healthcare Stocks to Buy Right Now” with publication date: May 01, 2018.

Among 29 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 25 have Buy rating, 0 Sell and 4 Hold. Therefore 86% are positive. Alexion Pharmaceuticals Inc. had 110 analyst reports since July 27, 2015 according to SRatingsIntel. Jefferies maintained the shares of ALXN in report on Wednesday, June 7 with “Hold” rating. BMO Capital Markets maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) rating on Friday, October 20. BMO Capital Markets has “Buy” rating and $177.0 target. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Buy” rating by Deutsche Bank on Thursday, November 3. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Buy” rating given on Friday, July 29 by Stifel Nicolaus. Jefferies maintained the shares of ALXN in report on Thursday, July 27 with “Hold” rating. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Strong Buy” rating given on Tuesday, September 1 by Raymond James. As per Friday, February 9, the company rating was maintained by Citigroup. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Neutral” rating by Credit Suisse on Wednesday, January 20. The firm has “Buy” rating given on Thursday, March 15 by Robert W. Baird. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Buy” rating given on Friday, July 28 by Morgan Stanley.

Investors sentiment decreased to 1.4 in 2017 Q4. Its down 1.93, from 3.33 in 2017Q3. It fall, as 1 investors sold SFBC shares while 4 reduced holdings. 1 funds opened positions while 6 raised stakes. 422,551 shares or 49.65% less from 839,178 shares in 2017Q3 were reported. Wells Fargo & Mn owns 300 shares or 0% of their US portfolio. Blackrock invested 0% of its portfolio in Sound Financial Bancorp, Inc. (NASDAQ:SFBC). Fj Cap Mngmt Llc has invested 0.38% in Sound Financial Bancorp, Inc. (NASDAQ:SFBC). Wasatch reported 0.04% stake. Alliancebernstein LP accumulated 78,648 shares. Vanguard Grp Inc invested in 0% or 13,961 shares. Wellington Llp reported 0% stake. Zpr Inv Mngmt has invested 0.36% in Sound Financial Bancorp, Inc. (NASDAQ:SFBC). Morgan Stanley reported 1 shares. Beese Fulmer Inv Mngmt accumulated 0.04% or 6,000 shares. Tradewinds Cap Limited Liability reported 1,000 shares or 0.02% of all its holdings. Oppenheimer And Close Ltd Limited Liability Company holds 48,218 shares. Deutsche Bank & Trust Ag reported 1,400 shares. Kennedy Capital Mgmt Inc reported 29,275 shares. Acadian Asset Mgmt Ltd Liability owns 1,102 shares or 0% of their US portfolio.

Fj Capital Management Llc, which manages about $217.40 million and $798.45M US Long portfolio, decreased its stake in Byline Bancorp Inc by 14,300 shares to 284,700 shares, valued at $6.54 million in 2017Q4, according to the filing. It also reduced its holding in First Cmnty Corp S C (NASDAQ:FCCO) by 50,500 shares in the quarter, leaving it with 305,500 shares, and cut its stake in Old Line Bancshares Inc (NASDAQ:OLBK).

Another recent and important Sound Financial Bancorp, Inc. (NASDAQ:SFBC) news was published by Nasdaq.com which published an article titled: “Sound Financial Bancorp, Inc. Reports Net Income of $1.6 Million for First Quarter 2018, or $0.62 per share” on April 26, 2018.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *